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Abstract Transcatheter arterial chemoembolization
(TACE)offersasurvivalbeneﬁttopatientswithintermediate
hepatocellular carcinoma (HCC). A widely accepted TACE
regimenincludesadministrationofdoxorubicin-oilemulsion
followed by gelatine sponge—conventional TACE.
Recently, a drug-eluting bead (DC Bead
) has been devel-
oped to enhance tumor drug delivery and reduce systemic
availability. This randomized trial compares conventional
TACE(cTACE) with TACEwith DC Bead forthe treatment
of cirrhotic patients with HCC. Two hundred twelve patients
withChild-PughA/Bcirrhosisandlargeand/ormultinodular,
unresectable, N0, M0 HCCs were randomized to receive
TACE with DC Bead loaded with doxorubicin or cTACE
with doxorubicin. Randomization was stratiﬁed according to
Child-Pugh status (A/B), performance status (ECOG 0/1),
bilobar disease (yes/no), and prior curative treatment (yes/
no). The primary endpoint was tumor response (EASL) at
6 months following independent, blinded review of MRI
studies. The drug-eluting bead group showed higher rates of
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compared with the cTACE group (27% vs. 22%, 52% vs.
44%, and 63% vs. 52%, respectively). The hypothesis of
superiority was not met (one-sided P = 0.11). However,
patients with Child-Pugh B, ECOG 1, bilobar disease, and
recurrent disease showed a signiﬁcant increase in objective
response (P = 0.038) compared to cTACE. DC Bead was
associated with improved tolerability, with a signiﬁcant
reduction in serious liver toxicity (P\0.001) and a signiﬁ-
cantly lower rate of doxorubicin-related side effects
(P = 0.0001). TACE with DC Bead and doxorubicin is safe
and effective in the treatment of HCC and offers a beneﬁt to
patients with more advanced disease.
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Introduction
Hepatocellular carcinoma (HCC) is an increasingly com-
mon tumor with a poor prognosis and limited systemic
treatment options; approximately 80% of patients die
within a year of diagnosis. In men, it is the ﬁfth most
common cancer worldwide and the third leading cause of
cancer-related death [1, 2].
Barcelona Clinic Liver Cancer (BCLC) tumor staging
[3, 4] combines the stage of liver disease, tumor stage,
clinical performance, and treatment options and is endorsed
by the European Association for the Study of Liver Disease
(EASL) and the American Association for the Study of
Liver Disease (AASLD) [5]. In countries where no sys-
tematic screening of cirrhotic patients is performed, 50–
75% are diagnosed when HCC is at an advanced stage
(BCLC Stage C, Child-Pugh A/B, cancer symptoms pres-
ent, and/or vascular invasion and extrahepatic spread) [6].
Such patients are precluded from surgery, and for many
years doxorubicin had been used for systemic treatment
[5], albeit without a proven survival beneﬁt [7]. Thus, there
is interest in new antiangiogenic agents. Recent data have
established Sorafenib as the preferred systemic therapy for
advanced HCC [8]. For unresectable intermediate-stage
HCC (BCLC Stage B, Child-Pugh A/B, with large or
multifocal HCC, no vascular invasion or extrahepatic
spread), the current standard treatment is transarterial
chemoembolization (TACE) [6].
TACE involves the periodic injection of a chemother-
apeutic agent, mixed with embolic material, administered
selectively into the feeding arteries of the tumor to
potentially obtain higher intratumor drug concentrations
compared to intravenous therapy, with occlusion of the
blood vessel causing infarction and necrosis [9]. In HCC
patients, TACE has achieved partial responses in up to
62% of patients, as well as signiﬁcantly delayed tumor
progression and vascular invasion [10–16]. Llovet et al.
were the ﬁrst to show a statistically signiﬁcant beneﬁt in
survival for chemoembolization using doxorubicin (50–
75 mg/m
2) and Gelfoam compared with best supportive
care (BSC) [16]. Although a survival beneﬁt of TACE
over symptomatic treatment or systematic chemotherapy
was demonstrated in a meta-analysis of randomized con-
trolled trials, overall survival at 3 years remained low
(\30%) for intermediate HCC patients [17]. A further
review failed to demonstrate either a survival difference
between TACE and embolization alone or superiority of
one chemotherapeutic agent over another [18]. Post-TACE
complications, e.g., acute liver or renal failure, encepha-
lopathy, ascites, and upper gastrointestinal bleeding, may
be severe [18]. There is therefore a requirement for
treatment regimens that improve response rates and sur-
vival, while reducing the risk of post-TACE
complications.
The DC Bead (Biocompatibles UK Ltd.) is a novel drug
delivery embolization system, comprising biocompatible,
nonresorbable hydrogel beads capable of being loaded
with anthracyclin derivatives such as doxorubicin [19, 20],
the most widely used chemotherapeutic for the treatment
of HCC. Preclinical [21, 22] and clinical [23, 24] studies
have shown that TACE with DC Bead results in higher
tumor concentrations and lower systemic concentrations
of doxorubicin compared to intra-arterial doxorubicin
and conventional TACE. Phase I/II studies in HCC
have demonstrated promising efﬁcacy with low toxicity
[23–26].
This phase II study is the ﬁrst comparative study
designed to evaluate the safety and efﬁcacy of DC Bead
with doxorubicin in the treatment of HCC in comparison
with conventional TACE (cTACE), the current standard
treatment [18].
Materials and Methods
Patients
Patients aged[18 years with HCC unsuitable for resection
or percutaneous ablation, (BCLC A/B, without portal
invasion or extrahepatic spread) were eligible for the study.
Eligibility criteria also included: no previous chemother-
apy, radiotherapy or transarterial embolization (with or
without chemotherapy), a conﬁrmed diagnosis of HCC
according to EASL, an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 or 1, and preserved
liver function (Child-Pugh Class A or B). Patients were
excluded if they had another primary tumor, advanced liver
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123disease (bilirubin levels [3 mg/dl, AST or ALT
[5 9 upper limit of normal or [250 U/l), advanced
tumoral disease (vascular invasion or extrahepatic spread,
or diffuse HCC, deﬁned as [50% liver involvement), or
contraindications for doxorubicin administration.
All patients provided written informed consent. The
study was performed in accordance with the Declaration of
Helsinki, the International Conference on Harmonization
Guideline on Good Clinical Practice, and relevant local
laws and regulations. Ethics committee approval was
obtained. Independent Data and Safety Monitoring Com-
mittees were established to monitor efﬁcacy and safety
data. The study was registered at www.clinicaltrials.gov
(NCT00261378), conducted according to the HCC Clinical
Trial Design guidelines [27], and reported according to
CONSORT recommendations [28, 29].
Study Design
This was an international, multicenter, prospective, ran-
domized, single-blind, phase II study. Patients were ran-
domized (1:1) to receive doxorubicin via TACE with DC
Bead or conventional TACE (cTACE). Randomization was
centralized, with stratiﬁcation factors of Child-Pugh class
(A/B), ECOG performance status (0/1), prior curative
(resection or percutaneous ablation) treatment (yes/no), and
bilobar disease (yes/no), representing more advanced dis-
ease. Randomized treatment allocation was predetermined
by an independent statistician and used a randomized
permuted block design to ensure that, at the conclusion of
the study treatment, group sizes were similar both overall
and for each level of stratiﬁcation factor. The randomiza-
tion was integrated into the web-based Case Report Form
after screening.
Dose selection was based on cTACE treatment protocols
of doxorubicin, 50–75 mg/m
2. Patients typically receive
between 100 and 150 mg in a single treatment session. In
two previous dose escalation studies [23, 24], DC Bead
loaded with doxorubicin in the range from 25 to 150 mg
was shown to be safe and effective even at the highest dose
of 150 mg.
In this study, patients in the DC Bead group received
4 ml DC Bead (1 vial of 300–500 lm ﬁrst, followed by 1
vial of 500–700 lm) loaded with doxorubicin (150 mg per
procedure) mixed with nonionic contrast medium. Lipiodol
(iodinated poppy seed oil; Guerbet, France) was not used.
No dose adjustment was made for bilirubin concentration
or body surface area. In the cTACE group, patients
received an intra-arterial injection of an emulsion of
doxorubicin (50–75 m
2 to a maximum of 150 mg, adjusted
for bilirubin concentration and body surface area) in lipi-
odol followed by particle embolization with an embolic
agent of the investigator’s choice (Gelfoam particles,
Embosphere, Contour SE, Bead Block, PVA particles). In
both treatment groups, patients were treated at 2-monhtly
intervals [25, 26], received a maximum of three chemo-
embolizations (at baseline, 2 months, and 4 months), and
were followed for 6 months. For patients with bilobar
disease who could not be treated superselectively in a
single treatment, a second embolization, of the alternative
lobe, was performed within 3 weeks of the ﬁrst procedure
(procedure 1B) provided that there was no contraindication
due to systemic toxicity and/or clinical performance.
Reasons for discontinuation of treatment included ineligi-
bility prior to chemoembolization, progressive disease, and
severe systemic toxicity.
In both treatment arms, catheterization was performed
via a femoral artery, and superselective embolization of the
hepatic artery branches feeding the tumor was performed.
The embolization endpoint was deﬁned as stasis in the
second- or third-order branches of the right or left hepatic
artery. A microcatheter could be used to select a branch
feeding the tumor.
Tumor response according to EASL criteria was evalu-
ated by magnetic resonance imaging (MRI) performed at
baseline and 1, 3, and 6 months (Fig. 1). MRI was per-
formed on 1.5-T scanners using a spoiled gradient-echo
T1-weighted sequence and fast spin-echo T2-weighted
sequence with fat suppression. A dynamic multiphasic,
contrast-enhanced, spoiled gradient-echo T1-weighted
sequence with arterial, portal, equilibrium, and delayed
phase was performed. MRI scans were assessed indepen-
dently by two assessors blinded to treatment allocation
(followed by adjudication in case of disagreement).
Study Hypothesis and Objective
The hypothesis was that treatment of HCC with DC Bead is
superior to treatment with cTACE. The objective was to
evaluate the safety and 6-month tumor response of
chemoembolization with DC Bead vs. cTACE.
Outcomes and Procedures/Assessments
Efﬁcacy
The primary efﬁcacy endpoint was the 6-month tumor
response rate, according to the amended EASL response
criteria, an accepted method for assessing tumor necrosis
following locoregional therapy [30]. According to this
amendment, response of target lesions is classiﬁed
according to the presence and the dimensions of the viable
tumor, deﬁned as a tumor that takes up contrast in the
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manually traced viable tumor on MRI slices obtained at
baseline and after treatment, and computer calculations
were made to quantify percentage changes in viable tumor
volume and therefore to deﬁne the response of target
lesions. The emergence of one or more new lesions was
considered evidence of progression in the overall patient
response assessment, regardless of the response obtained in
target lesions. Objective response rate (OR) was deﬁned as
complete response plus partial response, and disease con-
trol rate as OR plus stable disease.
Safety
The primary safety endpoint was the incidence of treat-
ment-related serious adverse events (SAEs) occurring
within 30 days of a treatment procedure. Secondary safety
outcomes included the incidence and severity of adverse
events (AEs) and SAEs, liver function parameters, labo-
ratory abnormalities, and cardiac function (ejection
fraction).
Statistical Analysis
The study aimed to reject with 80% power, at a one-sided
signiﬁcance level of a = 0.025, the null hypothesis H0,
i.e., pDC Bead = pcTACE against the alternative
hypothesis, H1, i.e., pDC Bead [ pcTACE, where p
denotes the rate of patients in the respective treatment arm
with an objective tumor response at 6 months. The study
was conducted using an adaptive three-stage group
sequential test design within the D class of critical values
from Wang and Tsiatis [31]. Assuming objective tumor
response rates of 55% (DC Bead) and 35% (cTACE), and a
total n = 200, the statistical power was approximately
81.3%. Interim analyses were conducted independently and
results kept conﬁdential until completion of the trial. Fol-
lowing each interim analysis, the Data Monitoring Com-
mittee made recommendations to continue, modify, or stop
the trial, based on interim analysis results (stopping criteria
at n1 = 60, boundary P-value = 0.00015; n2 = 40,
boundary P-value = 0.00258; n3 = 100, boundary P-
value = 0.02396).
DC Bead™ Group 
Baseline Assessments/Randomization                N=212 
Randomised           N=102         N=110 
Received  Treatment          N=93*      N=108*
0 4 = N 7 2 = N t n e m t a e r t d e u n i t n o c s i D
4 1 = N 2 1 = N t n e v e e s r e v d A
4 = N 3 = N l a w a r d h t i w t n e s n o c t n e i t a P
1 = N 0 = N y t i l i b i g i l e n i t n e s n o c t s o P
8 = N 2 = N y c a c i f f e f o k c a L
8 = N 5 = N d e g a t s n w o D
1 = N 2 = N p u - w o l l o F o t t s o L
3 = N 0 = N h t a e D
1 = N 3 = N r e h t O
Did not receive intervention   N=9          N=2 
0 = N 2 = N d e s u f e R
1 = N 4 = N a i r e t i r c n o i s u l c n i t e e m t o n d i D
0 = N 1 = N n o i s s e r g o r P
1 = N 2 = N r e h t O
8 0 1 = N 3 9 = N n o i t a l u p o P d e s y l a n A
cTACE Group Fig. 1 Flowchart of patients in
the PRECISION V Trial. * For
patients with bilobar disease
who could not be treated
superselectively in a single
treatment, a second
embolization was performed
(procedure 1B) for the
alternative lobe within 3 weeks
of the ﬁrst procedure: DC Bead
(n = 8) vs. cTACE (n = 5)
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Modiﬁed Intention-to-Treat (MITT) population, deﬁned as
all randomized patients who received at least one chemo-
embolization; this also deﬁned the safety population. The
primary safety endpoint was analyzed using the chi-square
test and all safety data are presented descriptively.
All other group comparisons were supportive in nature
and the secondary efﬁcacy endpoints were analyzed
descriptively using appropriate statistical methods for each
endpoint. Where statistical modeling was used, baseline
stratiﬁcation factors were included. All endpoints were also
presented using descriptive statistical methods and all sta-
tistical testing was two-sided at the 5% level of signiﬁ-
cance. The preplanned analyses of the subgroup of more
advanced patients (Child-Pugh B, ECOG 1, bilobar dis-
ease, recurrent disease) revealed a clinically relevant trend
toward a higher OR rate for DC Bead over cTACE. Sup-
plementary post hoc analyses focused on treatment
response and safety were therefore undertaken. The fre-
quency of doxorubicin-related AEs, and of overall AEs,
and the level of liver toxicity were explored further. These
data were hypothesis-generating in nature, and P-values
should be interpreted in the exploratory sense.
Results
Patients were enrolled at 19 centers in ﬁve countries
(France, Germany, Switzerland, Austria, and Greece)
between 25 November 2005 and 27 June 2007. A total of
212 patients were randomized to TACE with DC Bead
(n = 102) or cTACE (n = 110). Due to dropouts prior to
ﬁrst treatment, the MITT population included 93 and 108
patients. The last-observation-carried-forward (LOCF)
principle was used so that the primary endpoint could be
assessed using the full MITT population (Fig. 1). At
Table 1 Patient characteristics, health status, and tumor burden at baseline
Characteristic DC Bead (n = 93) cTACE (n = 108)
Age, years (mean ± SD) 67.3 ± 9.1 67.4 ± 8.8
Gender (male/female) 79/14 95/13
Etiology of cirrhosis
a (HCV/HBV/alcohol/other
b) 22/16/43/21 18/18/57/25
Health status
Prior curative treatment (no/yes)
c 82/11 95/13
Prior surgery
d 7 (7.5%) 9 (8.3%)
Radiofrequency ablation
d 5 (5.4%) 3 (2.8%)
Percutaneous ethanol injection
d 1 (1.1%) 2 (1.9%)
Thermoablation
d 0 2 (1.9%)
Bilobar disease (no/yes)
c 52/41 63/45
Child-Pugh classiﬁcation (A/B)
c 77/16 89/19
ECOG performance status (0/1)
c 74/19 80/28
Okuda tumor classiﬁcation (I/II) 79/14 103/5
BCLC classiﬁcation (A/B/C)
e 24/69/0 29/79/0
Karnofsky performance status (100/90/80/B70) 60/27/5/1 51/42/10/5
Encephalopathy (no/yes) 93/0 107/1
LVEF, % (mean ± SD) 66.2 ± 8.4 64.3 ± 8.2
Tumor burden
No. of nodules (1/1?
f/2/multinodular) 28/11/19/35 32/8/18/50
Mean no. of lesions (range) 2.8 (1–20) 3.8 (1–50)
Total sum of diameters of HCC lesions, mm (mean ± SD) 88.9 ± 52.1 89.2 ± 59.3)
Mean liver involvement, % (range) 16.1 (\10–50) 16.1 (\10–50)
a Multiple responses per patient were possible
b Autoimmune hepatitis, cryptogenic cirrhosis, haemochromatosis, hepatic cirrhosis due to prolonged cytostatic therapy, hepatic steatosis,
hepatitis D, non-cirrhotic and unknown
c Stratiﬁcation factors
d Type of prior curative treatments: number of patients (% of patients); multiple different curative treatments possible
e BCLC classiﬁcation according to tumor stage [32]
f 1?=1? satellite
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123baseline there were no major differences between the
treatment groups with regard to patient demographics,
tumor burden, or health status (Table 1). The majority of
patients (66.7%) in both groups were considered more
advanced, as they met the higher risk criteria for one or
more of the four prognostic factors, i.e., Child Pugh B,
ECOG 1, bilobar or recurrent disease (63 of 93 DC Bead
and 72 of 108 cTACE patients). The mean total dose of
doxorubicin administered was higher in the DC Bead group
compared with the cTACE group (295 vs. 223 mg) and in
all subgroups. The mean volume of lipiodol administered
was 10 ml per treatment in the cTACE group [32]. The
numbers of chemoembolizations in each treatment group
were similar: 93 and 108 patients, respectively, received a
ﬁrst; 82% of patients in each group received a second; and
61% and 57%, respectively, received a third
chemoembolization.
Efﬁcacy (Tumor Response—EASL)
At 6 months, a complete response was achieved in 25
(26.9%) vs. 24 (22.2%) patients, a partial response in 23
(24.7%) vs. 23 (21.3%) patients, and stable disease in 11
(11.8%) vs. 9 (8.3%) patients in the DC Bead vs. cTACE
arm, respectively. Progressive disease was observed in 30
(32.3%) vs. 44 (40.7%) patients, respectively; 4 DC Bead
patients and 8 cTACE patients withdrew prior to the ﬁrst
MRI scan. Reasons for these withdrawals were AEs (four
DC Bead and four cTACE), withdrawn consent (two
cTACE), and post consent ineligibility (two cTACE).
Therefore, the OR rate was 51.6% vs. 43.5% in the DC
Bead vs. cTACE arm, respectively; the hypothesis of
superiority was not met (one-sided P = 0.11) (Fig. 2). The
difference between groups in favor of DC Bead was
8.1% (two-sided 95% repeated conﬁdence interval (RCI),
-4.8 to 22.6%). The disease control rates were 63.4%
vs. 51.9%, respectively (two-sided P = 0.11). Boundary
P-values were not exceeded in the interim analyses.
Supplementary analyses showed that in the 67% of
patients with more advanced disease (Child Pugh B, ECOG
1, bilobar or recurrent disease), the incidence of OR and
disease control rates were statistically higher (P = 0.038
and P = 0.026, respectively) in the DC Bead compared
with the cTACE group (Fig. 2). The greatest difference in
disease control rates between DC Bead and cTACE
occurred in the ECOG 1 and Child-Pugh B subgroups
(both, 63% and 32%, respectively; Fig. 3).
Safety
There was no statistically signiﬁcant (P = 0.86) difference
between treatments for the primary safety endpoint (treat-
ment-related SAEs within 30 days of a procedure): 19
(20.4%) DC Bead patients experienced 28 events and 21
Fig. 2 Tumor response at 6 months (LOCF) (MITT population and
advanced patient group*
, **). * More advanced disease was at least
one of Child-Pugh B, ECOG 1, undergone prior curative treatment
(i.e., recurrent disease), and presence of bilobar disease. In accor-
dance with the EASL criteria: complete response (CR)—complete
disappearance of all known viable tumor (assessed via uptake of
contrast in the arterial phase of the MRI scan) and no new lesions;
partial response (PR)—50% reduction in viable tumor area of all
measurable lesions; stable disease (SD)—all other cases; progressive
disease (PD)—25% increase in size of one or more measurable
lesions or the appearance of new lesions. Objective response (OR)
was deﬁned as CR ? PR, and disease control (DC) as
CR ? PR ? SD. ** Analysis of advanced patient subgroup: OR
rate, P = 0.038; DC rate, P = 0.026; CR rate, P = 0.091 (chi-square
analysis)
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123(19.4%) cTACE patients experienced 24 events. Supple-
mentary post hoc analysis indicated that the incidence of
SAEs within 30 days of a procedure was consistently lower
in the DC Bead group both for the less advanced and for
the more advanced patients based on the four stratiﬁcation
factors (Table 2).
The overall frequency of treatment-emergent AEs (TE-
AEs) per 100 treatments was lower in the DC Bead com-
pared with the cTACE group, as were treatment-related
TEAEs, Southwestern Oncology Group (SWOG) toxicity
Grade 3 or 4 TEAEs, Grade 3 or 4 treatment-related TE-
AEs, and treatment-related SAEs. The majority of TEAEs
were mild or moderate in intensity, with a lower frequency
of severe events (20.4% vs. 30.6%) reported in DC Bead
vs. cTACE patients. The only event with a difference in
incidence of C10% was alopecia, reported in 2.2% of DC
Bead and 19.4% of cTACE patients. Serious liver toxicity
postchemoembolization was also lower in the DC Bead
group. Observed postprocedural increases in the liver
enzymes AST and ALT were signiﬁcantly less in the DC
Bead group than in the cTACE group. The mean maximum
ALT increase in the DC Bead group was 50% less than in
the cTACE group (95% CI, 39–65%; P\0.001) and 41%
less with respect to AST (95% CI, 46–76%; P\0.001)
(Fig. 4). Cardiac function (measured by echocardiography,
isotopic ventriculography, or MRI) was maintained in the
Fig. 3 a Complete response,
objective response, and disease
control rate (cumulative
number [%] of patients) of all
patients at 6 months. b
Complete response, objective
response, and disease control
rate (cumulative number [%] of
patients) of patients by
stratiﬁcation factors for
advanced disease at baseline
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123DC Bead group, whereas there was a deterioration in left
ventricular ejection fraction in the cTACE group (DC
Bead, ?2.7 ± 10.1 percentage points; cTACE, -1.5 ± 7.6
percentage points; P = 0.018). Sixteen deaths were
reported during the study (eight in each arm). Of these, two
DC Bead and six cTACE patients died within 30 days of a
procedure. Four patients died due to disease progression
(one DC Bead, three TACE). Other causes of death were
liver failure (two in each arm), cardiac events (two DC
Bead, one cTACE), infection (one DC Bead, two cTACE),
and, in one DC Bead patient, each of GI bleed and
unknown cause.
With regard to the systemic side effects of doxorubicin
(alopecia, skin discoloration, mucositis, and marrow sup-
pression), post hoc analyses established a signiﬁcant ben-
eﬁt (estimate of true incidence, -14.1%; 95% CI, -24.7%
to –3.5%; P=0.012) in favor of DC Bead over cTACE: 12
events in 11 (11.8%) patients vs. 40 events in 28 (25.9%)
patients, respectively. Alopecia, the most commonly
occurring event, was almost completely absent in DC Bead
patients (1 vs. 23 events). The only DC Bead alopecia
event was mild (Grade 1), while in the cTACE arm almost
half of the alopecia events (11 events) were of pronounced/
total hair loss (Grade 2). Marrow suppression and muco-
sitis were more common and of greater severity in cTACE
compared with DC Bead patients, and skin discoloration
occurred in equal numbers (Table 3).Using the assumption
of independence of events, the difference in frequencies of
doxorubicin-related events was also signiﬁcant
(P = 0.0001). The incidence and frequency of post
embolization syndrome events were comparable in the
treatment groups: 35 events in 23 (24.7%) DC Bead and 43
events in 28 (25.9%) cTACE patients.
Discussion
Currently, cTACE is the standard ﬁrst-line treatment for
patients with inoperable and intermediate HCC. Although
TACE has been in use for several years, the procedure
varies widely between centers, with different drugs
(doxorubicin, mitomycin, cisplatin, mixtures), embolic
agents, doses, and schedules used. Response rates vary and
evidence of a survival beneﬁt, particularly at 3 years, is
low [15–18]. In the PRECISION V study, cTACE was
designed to reﬂect the current practice of chemoemboli-
zation and was standardized to the use of doxorubicin,
lipiodol, and an embolic agent.
The DC Bead is a novel drug delivery embolization sys-
tem that has been designed to deliver a higher and more
sustained release of drug directly into the tumor and a low
release of drug into the systemic circulation, with the
intention to maximize the drug’s effectiveness in terms of
response, while signiﬁcantly reducing its systemic toxicity
[22]. Preclinical and clinical studies have demonstrated a
higher and prolonged retention of doxorubicin within the
tumorafterTACEwithDCBead,andlowersystemicplasma
levels of doxorubicin, compared to cTACE [19–24]. Varela
etal.reportedsigniﬁcantlylowerdoxorubicinCmaxandAUC
values in DC Bead patients (78.97 ± 38.3 ng/ml and
662.6 ± 417.6 ng/ml min) than in cTACE patients
(2341.5 ± 3951.9 ng/ml and 1812.2 ± 1093.7 ng/ml min;
P = 0.00002 and P = 0.001, respectively)[23]. In another
phaseI/IIclinicalstudyPoonetal.observedlowCmaxvalues
(52.8 ± 41.5 ng/ml) even at the highest possible loading of
doxorubicin (150 mg), with an average half-life of doxoru-
bicin in plasma of 73.5 ± 22.7 h [24]. Clinical pilot studies
in HCC have demonstrated promising efﬁcacy [23–26, 33].
The current study is the ﬁrst international, multicenter,
randomized study designed to evaluate the safety and
efﬁcacy of a drug-eluting bead (DC Bead) compared to
cTACE for the treatment of HCC. The 6-month OR rate of
52% observed following TACE with DC Bead in this study
compares well with previously reported OR rates of 44–
82% in phase I/II studies with DC Bead [23–26]. Although
in this study statistical superiority in OR rates compared to
cTACE could not be demonstrated, a trend toward higher
response rates in all categories (complete response, OR,
and disease control) was observed for DC Bead over
cTACE. Of particular note was the signiﬁcant reduction in
serious liver toxicity and doxorubicin side effects with DC
Bead, despite the higher mean total dose administered,
Table 2 Incidence of serious adverse events within 30 days of a
procedure, by stratiﬁcation (safety population)
Stratiﬁcation factor DC Bead (n = 93) cTACE (n = 108)
No. of
patients/total
% No. of
patients/total
%
All patients 22/93 23.7 32/108 29.6
Child-Pugh A 19/77 24.7 26/89 29.2
Child-Pugh B 3/16 18.8 6/19 31.6
ECOG 0 17/74 23.0 23/80 28.8
ECOG 1 5/19 26.3 9/28 32.1
Unilobar 12/52 23.1 18/63 28.6
Bilobar 10/41 24.4 14/45 31.1
No prior curative
treatments
19/82 23.2 28/95 29.5
Recurrent disease 3/11 27.3 4/13 30.8
Note: Serious adverse events were deﬁned as events (1) resulting in
death, (2) that were immediately life-threatening, (3) resulting in
permanent or signiﬁcant disability/incapacity, or (4) requiring or
extending inpatient hospitalization or (5) congenital anomaly/birth
defects. Analysis of treatment groups overall: chi-square test,
P = 0.34; difference in incidence rates, -6.0%; 95% CI, -18.2 to 6.2
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doxorubicin compared to cTACE.
Post hoc analyses of the predeﬁned stratiﬁed groups of
higher-risk patients demonstrated that DC Bead provided
signiﬁcant advantages in treating patients with more
advanced disease, where improved response and disease
control and good tolerability were achieved. This ﬁnding
is of particular signiﬁcance for Child-Pugh B and ECOG
1 patients, for whom treatment with chemoembolization
has been controversial [6]. Contrary to the observation in
the cTACE arm, the response rate for DC Bead in these
subgroups was maintained. This suggests that the
improved tolerability of DC Bead allows treatment to be
repeated according to planned schedule even in these
more vulnerable patients. These favorable results estab-
lish DC Bead as a viable embolic agent for studies
evaluating the combination of TACE with systemic
administration of targeted agents such as Sorafenib, in
intermediate HCC. In advanced HCC, Sorafenib has
shown a survival beneﬁt with low radiological response
rates [27–29].
A limitation of the current study is that the number of
patients required to show statistically signiﬁcant superior-
ity was underestimated due to the higher response rate of
cTACE (44%) compared with the original assumption
(35%) [16]. Robust time-to-progression and survival data
would require further randomized controlled trials with
longer follow-ups.
In conclusion, TACE with DC Bead and doxorubicin is
safe and effective in the treatment of intermediate-stage
HCC and offers beneﬁt to patients with more advanced
disease.
Fig. 4 Comparison of
treatment groups for-fold
changes in liver enzymes by
chemoembolization procedure
and maximum-fold change
across all procedures (mean,
95% conﬁdence interval [CI]).
Analysis using t-test for log-
transformed data; results back-
transformed to ratio scale for
presentation. Procedure 1B not
shown due to small sample
size. a Alanine
aminotransferase (ALT):
procedures 1 and 2 and
maximum across all
procedures, P\0.001;
procedure 3, P = 0.004. b
Aspartate aminotransferase
(AST): procedure 1,
P = 0.001; procedure 2 and
maximum across all
procedures, P\0.001;
procedure 3, P = 0.06
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